CONMED (CNMD) Hisse Özeti
Bir tıbbi teknoloji şirketi olan CONMED Corporation, cerrahi prosedürler için cihazlar ve ekipmanlar geliştirmekte, üretmekte ve satmaktadır. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 5/6 |
| Gelecekteki Büyüme | 3/6 |
| Geçmiş Performans | 1/6 |
| Finansal Sağlık | 3/6 |
| Temettüler | 0/6 |
Ödüller
Risk Analizi
CNMD Community Fair Values
Create NarrativeSee what 7 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
CONMED Corporation Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | US$51.07 |
| 52 Haftanın En Yüksek Seviyesi | US$56.64 |
| 52 Haftanın En Düşük Seviyesi | US$31.44 |
| Beta | 0.90 |
| 1 Aylık Değişim | 21.60% |
| 3 Aylık Değişim | 37.17% |
| 1 Yıllık Değişim | -8.49% |
| 3 Yıllık Değişim | -52.70% |
| 5 Yıllık Değişim | -62.02% |
| Halka arzdan bu yana değişim | 2,453.50% |
Son Haberler & Güncellemeler
Seeking Alpha • Aug 18
CONMED Corporation: Organic Growth Is Masked By Divestitures
Summary Conmed's headline growth appeared flat at $343 million in the last quarter, but organic growth actually increased by 6%, with the leading segment being the orthopedic surgery business. Growth was offset by the divestiture of the GI business; as a result, growth metrics look poor with a quant rating of F and below the sector growth. When I adjust for organic growth, impressive profitability, and a buyback story, Conmed stock looks highly undervalued below the sector multiple. and I am rating it a buy. Read the full article on Seeking Alpha
Anlatı Güncellemesi • Aug 14
CNMD: Gastro Exit And Potential Sale Interest Will Shape Future Upside
Analysts have raised the implied fair value for CONMED to $45.50 from $39.60, reflecting higher Street price targets clustered around $45 after recent Q2 outperformance, one-time tariff benefits, and renewed interest from potential financial and strategic buyers. Analyst Commentary Recent research on Conmed shows a split between investors focused on potential sale value and those focused on execution risks and relative appeal within medtech.
Anlatı Güncellemesi • Jul 31
CNMD: Potential Sale And Surgical Reset Will Shape Next Chapter
Analysts have lifted their fair value estimate for Conmed to $49 from $40. This reflects updated assumptions on growth, profitability, and future P/E that are broadly consistent with recent price target increases to $45 and commentary around potential sale scenarios in the $46 to $53 range.
Anlatı Güncellemesi • Jul 16
CNMD: Sale Hopes Will Face Debt And Execution Headwinds Through 2026
CONMED's analyst price target has been modestly reset closer to $36, as analysts weigh slightly higher modeled revenue growth and margins against updated assumptions around valuation multiples and the potential for private equity interest highlighted in recent research. Analyst Commentary Recent research on CONMED reflects a mixed backdrop, with several firms taking a more cautious stance even as takeover speculation and private equity interest attract attention.Recent updates
Seeking Alpha • Aug 18
CONMED Corporation: Organic Growth Is Masked By Divestitures
Summary Conmed's headline growth appeared flat at $343 million in the last quarter, but organic growth actually increased by 6%, with the leading segment being the orthopedic surgery business. Growth was offset by the divestiture of the GI business; as a result, growth metrics look poor with a quant rating of F and below the sector growth. When I adjust for organic growth, impressive profitability, and a buyback story, Conmed stock looks highly undervalued below the sector multiple. and I am rating it a buy. Read the full article on Seeking AlphaAnlatı Güncellemesi • Aug 14
CNMD: Gastro Exit And Potential Sale Interest Will Shape Future Upside
Analysts have raised the implied fair value for CONMED to $45.50 from $39.60, reflecting higher Street price targets clustered around $45 after recent Q2 outperformance, one-time tariff benefits, and renewed interest from potential financial and strategic buyers. Analyst Commentary Recent research on Conmed shows a split between investors focused on potential sale value and those focused on execution risks and relative appeal within medtech.Anlatı Güncellemesi • Jul 31
CNMD: Potential Sale And Surgical Reset Will Shape Next Chapter
Analysts have lifted their fair value estimate for Conmed to $49 from $40. This reflects updated assumptions on growth, profitability, and future P/E that are broadly consistent with recent price target increases to $45 and commentary around potential sale scenarios in the $46 to $53 range.Anlatı Güncellemesi • Jul 16
CNMD: Sale Hopes Will Face Debt And Execution Headwinds Through 2026
CONMED's analyst price target has been modestly reset closer to $36, as analysts weigh slightly higher modeled revenue growth and margins against updated assumptions around valuation multiples and the potential for private equity interest highlighted in recent research. Analyst Commentary Recent research on CONMED reflects a mixed backdrop, with several firms taking a more cautious stance even as takeover speculation and private equity interest attract attention.Anlatı Güncellemesi • Jul 02
CNMD: Gastro Exit And Buybacks Will Support Future Profit Margin Upside
Analysts have lowered their price expectations for CONMED, with the updated target moving to $40. This reflects a shift toward lower assumed revenue growth and P/E multiples, even as projected profit margins edge higher in their models.Anlatı Güncellemesi • Jun 18
CNMD: Refocused Surgical Portfolio And Buybacks Will Test Medtech Reset
Analysts have reset their price target on CONMED to $40, down from $52, citing a broader reassessment of medtech valuations in a year with fewer product cycles, along with rising concerns around healthcare utilization and inflation. Analyst Commentary Recent commentary on CONMED highlights that the lower US$40 price target sits within a broader reset for medtech valuations, rather than being tied to a single company specific issue.Anlatı Güncellemesi • Jun 04
CNMD: Reset Medtech Expectations Will Set Stage For 2026 Guidance Reassessment
Analysts have trimmed their price targets on CONMED, with figures such as BofA cutting its target to $40 and another firm moving to $39. This reflects a reset in medtech valuations, as well as concerns around product execution and limited near term catalysts.Anlatı Güncellemesi • May 20
CNMD: Execution And Margin Stability Will Be Tested In Medtech Reset
Analysts have reduced CONMED's fair value estimate and price target to $40 from $52. They cite a reset in medtech valuations, concerns around product cycles and utilization, and a lower assumed future P/E multiple, while keeping revenue growth and profit margin assumptions broadly steady.Anlatı Güncellemesi • May 01
CNMD: Execution Repairs And Margin Stability Will Support Future Upside
Narrative Update Overview Analysts have trimmed their average price targets on CONMED by $3, alongside neutral ratings and concerns around product execution and a lack of near term catalysts, even as updated assumptions reflect steady revenue growth, profit margins around 10.8% and a slightly lower future P/E multiple. Analyst Commentary Recent research on CONMED has centered on valuation reset, execution around key products, and the search for clear catalysts, with JPMorgan trimming its price target by $3 and other firms shifting to more neutral stances.Anlatı Güncellemesi • Apr 17
CNMD: Execution Questions And Limited Catalysts Will Shape Balanced Risk Profile
Analysts have reset their price target on CONMED to $39, trimming it by $16 from the prior $55. They cite concerns around AirSeal competition, recent execution issues, and a lack of clear near term catalysts for a turnaround in sentiment.Anlatı Güncellemesi • Apr 02
CNMD: Execution Rebound And Margin Focus Will Support Future Upside
The analyst price target for CONMED has been reduced by $3 to $52, as analysts factor in a slightly higher discount rate and a lower future P/E multiple while still modeling modestly higher revenue growth and profit margins, and acknowledging recent downgrades that highlight concerns around execution and a lack of near term catalysts. Analyst Commentary Recent research on CONMED reflects a mixed setup, with some analysts focused on execution risks and a lack of clear near term catalysts, while others maintain a more balanced stance that supports a mid range valuation and steady expectations.Anlatı Güncellemesi • Mar 18
CNMD: Execution Concerns And Leadership Transition Will Shape Balanced Risk Profile
Narrative Update: CONMED Price Target Shift The analyst price target for CONMED has been revised from $42 to $39, with analysts pointing to execution missteps, weaker sentiment around the AirSeal product, and a lack of clear near term catalysts as key reasons for the adjustment. Analyst Commentary Recent Street research on CONMED has tilted more cautious, with several bearish analysts highlighting execution risk, questions around AirSeal, and a limited near term catalyst path to re-rate the shares.Anlatı Güncellemesi • Mar 04
CNMD: Portfolio Refocus And Leadership Change Will Shape Balanced Risk Profile
Narrative Update on CONMED Analysts kept their $42 price target for CONMED unchanged. They cited slightly higher assumed revenue growth and profit margins along with a modestly lower discount rate and future P/E, which together support a steady valuation view despite ongoing sector volatility highlighted in recent research.Anlatı Güncellemesi • Feb 17
CNMD: Portfolio Refocus And Higher Future P/E Will Support Returns
Analysts maintained their fair value estimate for CONMED at $55.00 and refreshed their price target framework to incorporate more conservative assumptions for revenue growth and profit margins, while also reflecting a higher future P/E multiple. Analyst Commentary Bullish analysts appear comfortable holding their US$55.00 fair value estimate for CONMED while updating models to reflect more conservative assumptions for revenue growth and margins.Anlatı Güncellemesi • Feb 03
CNMD: Future Portfolio Shift And Capital Moves Signal Balanced Risk Profile
Analysts have reduced their price target on CONMED to US$42 from US$55, citing a higher discount rate, more conservative revenue growth assumptions, improved profit margin expectations, and a lower future P/E multiple in their updated models. Analyst Commentary Bearish analysts are using the lower US$42 price target as a signal that they see less room for upside in CONMED at current levels, especially when they factor in higher discount rates and more cautious revenue assumptions.Anlatı Güncellemesi • Jan 19
CNMD: Gastro Exit And Buybacks Will Support Future Margin Expansion
Analysts modestly adjusted their price target for CONMED, citing a slightly lower discount rate, unchanged fair value of $48.40, and minimal tweaks to long term growth and P/E assumptions that together fine tune their outlook rather than overhaul it. Analyst Commentary Bullish Takeaways Bullish analysts see the steady fair value estimate of $48.40, together with the slightly lower discount rate, as a sign that their view on CONMED’s risk profile and long term earnings power remains intact even after recent fine tuning.Anlatı Güncellemesi • Jan 05
CNMD: Gastro Exit And Buybacks Will Support Margin Expansion Ahead
Analysts have trimmed their price target for CONMED to about US$48.40 from roughly US$54.00, pointing to slightly lower growth assumptions and a reduced future P/E multiple, partly balanced by a marginally higher profit margin outlook. What's in the News CONMED plans to exit its gastroenterology product lines, aiming to focus resources on core areas such as minimally invasive, robotic and laparoscopic surgery, smoke evacuation, and orthopedic soft tissue repair (Key Developments).Anlatı Güncellemesi • Dec 20
CNMD: Focused Surgical Portfolio And Buybacks Will Support Stronger Future Returns
Analysts have lowered their price target on CONMED from 80.00 dollars to 55.00 dollars, citing slightly slower expected revenue growth and a higher discount rate that more than offset improved margin and valuation assumptions. What's in the News CONMED will exit its gastroenterology product lines to focus resources on core areas including minimally invasive, robotic, and laparoscopic surgery, smoke evacuation, and orthopedic soft tissue repair.Anlatı Güncellemesi • Dec 06
CNMD: Margin Expansion And Buyback Program Will Drive Strong Future Returns
Analysts have nudged their price target on CONMED slightly higher to $54, citing modestly lower discount rate and revenue growth assumptions, offset by a slightly improved profit margin outlook and a marginally lower future P/E multiple that together support a stable valuation profile. Analyst Commentary Analyst views on CONMED remain balanced, with recent model tweaks reflecting a more nuanced outlook on growth, profitability, and valuation.Anlatı Güncellemesi • Nov 22
CNMD: Margin Initiatives And Robust Buyback Will Drive Long-Term Shareholder Value
CONMED's analyst price target has been reduced from $56 to $54 per share, as analysts cite modest cuts to growth and profit outlooks, along with slightly higher discount rates following recent sector updates. Analyst Commentary Analysts have provided a range of perspectives on CONMED’s outlook based on recent developments in company performance and sector trends.Anlatı Güncellemesi • Nov 07
CNMD: Improving Profit Margins And Robust Buyback Program Will Drive Shareholder Value
CONMED's analyst price target has been lowered from $61 to $56. This change reflects a more cautious stance as analysts point to expectations of slower revenue growth and a higher discount rate, despite improvements in underlying profit margins and future valuation multiples.Analiz Makalesi • Oct 06
These 4 Measures Indicate That CONMED (NYSE:CNMD) Is Using Debt Reasonably Well
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analiz Makalesi • Sep 12
CONMED (NYSE:CNMD) Has Announced A Dividend Of $0.20
CONMED Corporation ( NYSE:CNMD ) has announced that it will pay a dividend of $0.20 per share on the 3rd of October...Analiz Makalesi • Aug 08
CONMED's (NYSE:CNMD) Solid Profits Have Weak Fundamentals
CONMED Corporation ( NYSE:CNMD ) just reported some strong earnings, and the market reacted accordingly with a healthy...Analiz Makalesi • Jul 03
Are Investors Undervaluing CONMED Corporation (NYSE:CNMD) By 49%?
Key Insights Using the 2 Stage Free Cash Flow to Equity, CONMED fair value estimate is US$107 Current share price of...Analiz Makalesi • May 24
CONMED (NYSE:CNMD) Is Paying Out A Dividend Of $0.20
CONMED Corporation ( NYSE:CNMD ) will pay a dividend of $0.20 on the 3rd of July. This means the dividend yield will be...Analiz Makalesi • May 17
CONMED Corporation's (NYSE:CNMD) Shares Bounce 26% But Its Business Still Trails The Market
Those holding CONMED Corporation ( NYSE:CNMD ) shares would be relieved that the share price has rebounded 26% in the...Analiz Makalesi • Mar 31
Is CONMED (NYSE:CNMD) Using Too Much Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Seeking Alpha • Feb 28
Repeated Disappointments On Growth And Margins Leaves Conmed Even Deeper In The Doghouse
Summary Conmed's ambitious revenue growth targets and ongoing operational issues have led to underperformance, with shares down 10% since my last update and ongoing concerns about growth, margins, and tariffs. Despite a decent Q4, Conmed's 2025 guidance was disappointing, with no margin expansion expected and a need to remediate supply and inventory issues. The threatened 25% tariff on goods imported from Mexico could severely affect earnings, adding to the company's existing operational and competitive challenges. While Conmed's valuation appears undemanding, significant risks and uncertainties suggest it may be prudent to wait for clearer signs of improvement before investing. Read the full article on Seeking AlphaAnaliz Makalesi • Feb 28
CONMED (NYSE:CNMD) Is Paying Out A Dividend Of $0.20
CONMED Corporation ( NYSE:CNMD ) will pay a dividend of $0.20 on the 4th of April. This means the dividend yield will...Analiz Makalesi • Feb 08
CONMED Corporation Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Shareholders might have noticed that CONMED Corporation ( NYSE:CNMD ) filed its full-year result this time last week...Hissedar Getirileri
| CNMD | US Medical Equipment | US Pazar | |
|---|---|---|---|
| 7D | 1.3% | 0.4% | -1.5% |
| 1Y | -8.5% | -12.6% | 17.9% |
Getiri vs. Endüstri: CNMD geçen yıl % -12.6 oranında getiri sağlayan US Medical Equipment sektörünü aştı.
Getiri vs Piyasa: CNMD geçen yıl % 17.9 oranında getiri sağlayan US Piyasasının altında performans gösterdi.
Fiyat Oynaklığı
| CNMD volatility | |
|---|---|
| CNMD Average Weekly Movement | 8.5% |
| Medical Equipment Industry Average Movement | 8.4% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
İstikrarlı Hisse Senedi Fiyatı: CNMD son 3 ayda US piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.
Zaman İçindeki Volatilite: CNMD 'nin haftalık oynaklığı ( 8% ) son bir yıldır istikrarlı seyretti.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 1970 | 3,900 | Pat Beyer | www.conmed.com |
Bir tıbbi teknoloji şirketi olan CONMED Corporation, cerrahi prosedürler için cihazlar ve ekipmanlar geliştirmekte, üretmekte ve satmaktadır. Şirket, ortopedik cerrahlara yumuşak doku yaralanmalarının güçlendirilmesi ve onarımı için klinik çözümler sunan BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors ve Agro Knotless Suture Anchors gibi ortopedik cerrahi ürünlerinin yanı sıra, cerrahların minimal invaziv spor hekimliği ameliyatları gerçekleştirmesini sağlayan elektrikli rezeksiyon aletleri, sıvı yönetimi ve görselleştirme sistemleri ve ilgili tek kullanımlık ürünleri içeren destekleyici ürünler sunmaktadır. Ayrıca Hall surgical markası altında ortopedik, artroskopik, oral/maksillofasiyal, podiatrik, spinal ve kardiyotorasik ameliyatlarda kullanılmak üzere pille çalışan, otoklavlanabilir, büyük ve küçük kemik elektrikli alet sistemleri sunmaktadır.
CONMED Corporation Temel Bilgiler Özeti
| CNMD temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | US$1.54b |
| Kazançlar(TTM) | US$56.50m |
| Gelir(TTM) | US$1.37b |
27.1x
F/K Oranı1.1x
P/S OranıCNMD aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| CNMD gelir tablosu (TTM) | |
|---|---|
| Gelir | US$1.37b |
| Gelir Maliyeti | US$609.35m |
| Brüt Kâr | US$762.31m |
| Diğer Giderler | US$705.81m |
| Kazançlar | US$56.50m |
Son Raporlanan Kazançlar
Jun 30, 2026
Sonraki Kazanç Tarihi
n/a
| Hisse başına kazanç (EPS) | 1.89 |
| Brüt Marj | 55.58% |
| Net Kâr Marjı | 4.12% |
| Borç/Özkaynak Oranı | 80.0% |
CNMD uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/08/21 20:41 |
| Gün Sonu Hisse Fiyatı | 2026/08/21 00:00 |
| Kazançlar | 2026/06/30 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
CONMED Corporation 16 Bu analistlerden 7, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Travis Steed | Barclays |
| Vikramjeet Chopra | BMO Capital Markets Equity Research |
| Travis Steed | BofA Global Research |